AstraZeneca plc (ADR)(NYSE:AZN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $5.60B. Analysts estimated a revenue of $5.68B. Earnings per share were $0.83. Analysts had estimated an EPS of $0.76.
In a different note, Argus Research said it Initiates Coverage on AstraZeneca plc (ADR), according to a research note issued on Jul 12, 2016. The shares have been rated ‘Hold’ by the firm. On May 2, 2016, Leerink Swann said it Maintains its rating on AstraZeneca plc (ADR). In the research note, the firm Lowers the price-target to $38.00 per share. The shares have been rated ‘Market Perform’ by the firm.
AstraZeneca plc (ADR) (AZN) made into the market gainers list on Thursdays trading session with the shares advancing 0.62% or 0.21 points. Due to strong positive momentum, the stock ended at $34.3, which is also near the day’s high of $34.46. The stock began the session at $34.07 and the volume stood at 67,66,477 shares. The 52-week high of the shares is $34.88 and the 52 week low is $26.97. The company has a current market capitalization of $86,779 M and it has 2,53,00,00,000 shares in outstanding.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory inflammation and autoimmunity and infection neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia bipolar disorder and depressive disorder and Synagis for RSV (respiratory syncytial virus) a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9) a treatment for hyperkalaemia a condition associated with increased mortality in patients with chronic kidney disease (CKD) diabetes mellitus (DM) and chronic heart failure (CHF).